Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade C $3.05 3.39% 0.1
ACRX closed up 3.39 percent on Wednesday, March 22, 2017, on 74 percent of normal volume. It was able to find support at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical ACRX trend table...

Date Alert Name Type % Chg
Mar 22 50 DMA Support Bullish 0.00%
Mar 22 200 DMA Resistance Bearish 0.00%
Mar 22 Stochastic Buy Signal Bullish 0.00%
Mar 22 Lower Bollinger Band Walk Other 0.00%
Mar 21 50 DMA Support Bullish 3.39%
Mar 21 200 DMA Resistance Bearish 3.39%
Mar 20 200 DMA Resistance Bearish 0.00%
Mar 20 Shooting Star Candlestick Bearish 0.00%
Mar 20 Bollinger Band Squeeze Range Contraction 0.00%
Mar 17 NR7 Range Contraction 1.67%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company’s principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. In addition, the company’s product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.08
52 Week Low 2.4
Average Volume 209,505
200-Day Moving Average 3.0988
50-Day Moving Average 2.957
20-Day Moving Average 3.1175
10-Day Moving Average 3.08
Average True Range 0.1616
ADX 17.71
+DI 24.07
-DI: 21.3
Chandelier Exit (Long, 3 ATRs) 3.1152
Chandelier Exit (Short, 3 ATRs) 3.3348
Upper Bollinger Band 3.3303
Lower Bollinger Band 2.9047
Percent B (%b) 0.34
Bandwidth 0.13652